HLA traveled a long distance from initially being regarded as a transplant antigen to becoming a molecule of interest in the 21st century for the development of novel diagnostics and therapeutics in the treatment of human diseases, vaccine design, pharmacogenetics, and genomics. The proteins encoded by genes in Human Leukocyte Antigen (HLA) complex regulate the innate and adaptive arms of human immune responsiveness through antigen recognition, and presentation, inflammation regulation, and the complement system, and the impact of this region is well documented in solid organ and hematopoietic stem cell transplantation, and in various immune-mediated conditions. In the 21st century, the role of HLA in personalized medicine is tailored with the advent of massive parallel sequencing technologies such as targeted sequencing by next-generation sequencing (NGS) and third-generation sequencing (TGS), which opens new frontiers in the development of predictive and preventive medicine.

The editors of this research topic invite all the researchers to submit their original research, and reviews or minireview articles to present and/or summarize the recent advancement on this topic illustrated below, which are for guidance purposes but are not limited to the following:

• HLA antigens, epitope matching, and in solid organ transplantation to prevent transplant rejection and management of immunosuppression
• Assessment of Donor specific anti-HLA antibodies in solid organ transplantation
• HLA matching in hematopoietic stem cell transplantation
• HLA disease association studies
• HLA association with infectious disease
• HLA association studies in cancer immunotherapy, and vaccine design.
• HLA functional studies in human and animal models
• Development of novel experimental methods and approaches for sequencing HLA regions, and resolving ambiguities
• HLA gene editing studies

Manuscripts covering pure bioinformatic analyses are not in the scope of the Immunogenetics section of Frontiers in Genetics. Experimental (wet lab) validation of the in silico obtained results is a prerequisite for peer review. Further, reports oriented towards the application of genetic analyses in oncological disease are not to be primarily targeted to the Immunogenetics unless they evolve in detail around the MHC (HLA) or other major immunogenetic systems and how those affect immune response and or therapy documented by real laboratory and/or clinical data, not solely bioinformatic analyses.

Submit your idea

Impact

Frontiers in Genetics

Impact